A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer
Francesco Grossi(University of Insubria), Enzo Galligioni(Ospedale Santa Chiara), Vittorio Gebbia(Università degli Studi di Enna Kore), Luca Moscetti(Ospedale di Belcolle), Orazio Caffo(Ospedale Santa Chiara), Teresa Gamucci, Francesco Ferraù(Université Paris-Sud), Davide Dondi(Sanofi (Italy)), Luca Boni(Ospedale Policlinico San Martino), Filippo de Marinis(Carlo Forlanini Hospital), Mario Nardi(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 3
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k